Chronic Disease Flexible Coverage Act
Official title: To codify Internal Revenue Service guidance relating to treatment of certain services and items for chronic conditions as meeting the preventive care deductible safe harbor for purposes of high deductible health plans in connection with health savings accounts.
What Do You Think?
How would you vote?
Vote to see the result.
What Happened in Congress?
March 4, 2025
- HousePassed by voice vote
Where the Bill Stands
- Introduced, done
- Committee, done
- Floor Vote, done
- Outcome, current stage
What This Bill Does
This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.
Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold.
The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include
- angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;
- anti-resorptive therapy for individuals with osteoporosis or osteopenia;
- beta-blockers for individuals with congestive heart failure or coronary artery disease;
- blood pressure monitors for individuals with hypertension;
- inhaled corticosteroids and peak flow meters for individuals with asthma;
- insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;
- international normalized ratio testing for individuals with liver disease or bleeding disorders;
- low-density lipoprotein testing for individuals with heart disease;
- statins for individuals with heart disease or diabetes; and
- selective serotonin reuptake inhibitors for individuals with depression.
The bill provides statutory authority for the IRS's guidance.
Sponsors
Related Documents
Timeline
- SenateReceived in the Senate and Read twice and referred to the Committee on Finance.
- House floor actionsMr. Smith (MO) moved to suspend the rules and pass the bill.
- Passed the House
- Library of CongressIntroduced in House
- House floor actionsReferred to the House Committee on Ways and Means.
- Introduced
- Committee




Comments
Comments with insults, hate speech or personal information are removed.